The biopharmaceutical company lycera has announced a collaboration agreement with Merck, Sharpe & Dohme (MSD) that will focus on developing and commercializing small-molecule therapies for treating a range of autoimmune diseases.
The biopharmaceutical company lycera has announced a collaboration agreement with Merck, Sharpe & Dohme (MSD) that will focus on developing and commercialising small-molecule therapies for treating a range of autoimmune diseases.
Under the terms of the agreement, Lycera will receive an upfront payment and research funding, and is also eligible to receive more than $300 million in research, development, regulatory and commercialisation milestone payments. MSD will be responsible for clinical development and will have global marketing and commercialisation rights to any products that may be developed. Lycera will be entitled to royalty payments, and development and sales milestones, on global sales from any products resulting from the collaboration.
The collaboration builds on a previous agreement between the two companies, announced in 2011, targeting the retinoic acid related orphan receptor (RORγt), which is a key transcription factor coordinating the differentiation of T-helper 17 cells and the production of highly pro-inflammatory mediators, such as interleukin-17.
In a statement, Rupert Vessey, senior vice president, global scientific strategy, at Merck Research Laboratories, said, “There are substantial unmet medical needs and opportunities in autoimmune disorders, and new targets representing attractive opportunities that we are very pleased to pursue through our new collaboration with Lycera.”
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.